We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.57%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.86B
AUM Growth
-$642M
Cap. Flow
-$108M
Cap. Flow %
-2.23%
Top 10 Hldgs %
44.28%
Holding
142
New
24
Increased
23
Reduced
21
Closed
24

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$127M
2
EW icon
Edwards Lifesciences
EW
+$80.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$78.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$43.5M
5
CYTK icon
Cytokinetics
CYTK
+$42.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$81.3M
2
ELV icon
Elevance Health
ELV
+$55.2M
3
BIIB icon
Biogen
BIIB
+$51.3M
4
MRK icon
Merck
MRK
+$50.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
126
CALL
Geron
GERN
$917M
– –
-400,000
Closed -$1.82M
ICLR icon
127
Icon
ICLR
$13.7B
– –
-123,900
Closed -$35.6M
LXRX icon
128
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-11,024,000
Closed -$17.3M
MRNA icon
129
CALL
Moderna
MRNA
$22B
– –
-100,000
Closed -$6.68M
OSCR icon
130
Oscar Health
OSCR
$9.41B
– –
-351,618
Closed -$7.46M
PCVX icon
131
Vaxcyte
PCVX
$7.71B
– –
-387,000
Closed -$44.2M
PHAT icon
132
Phathom Pharmaceuticals
PHAT
$936M
– –
-1,449,073
Closed -$26.2M
REGN icon
133
Regeneron Pharmaceuticals
REGN
$73.2B
– –
-45,200
Closed -$47.5M
RNAM
134
CALL
DELISTED
Avidity Biosciences
RNAM
– –
-100,000
Closed -$4.59M
FLNA
135
PUT
Filana Therapeutics
FLNA
$42.2M
– –
-95,000
Closed -$2.8M
SNDX icon
136
Syndax Pharmaceuticals
SNDX
$1.68B
– –
-1,925,300
Closed -$37.1M
SRPT icon
137
CALL
Sarepta Therapeutics
SRPT
$1.62B
– –
-50,000
Closed -$6.24M
TELA icon
138
TELA Bio
TELA
$30.9M
– –
-2,161,185
Closed -$5.47M
VIGL
139
DELISTED
Vigil Neuroscience
VIGL
– –
-448,891
Closed -$1.53M
SOLV icon
140
CALL
Solventum
SOLV
$15B
– –
-69,300
Closed -$4.83M
LBPH
141
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-170,000
Closed -$5.67M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2024 Portfolio in Review

As of Q4 2024, OrbiMed held 142 positions worth $4.86B, down 12% from $5.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed's Q4 2024 filing shows 24 new, 23 increased, 21 reduced and 24 closed positions. Its largest new stake was Upstream Bio Inc: 5,693,589 shares worth $93.6M. The largest sale was Amgen, an estimated $81.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • OrbiMed's largest Q4 2024 buy was Upstream Bio Inc: 5,693,589 shares worth $93.6M.
  • OrbiMed added most to Neurocrine Biosciences in Q4 2024, an estimated $78.7M increase.
  • OrbiMed's biggest Q4 2024 reduction was Biogen, cutting an estimated $51.3M.
  • OrbiMed fully exited Amgen in Q4 2024, selling an estimated $81.3M.
  • OrbiMed's ten largest holdings make up 44% of its $4.86B portfolio in Q4 2024.
  • OrbiMed opened 24 new positions and closed 24 in Q4 2024.
  • OrbiMed's portfolio value fell 12% quarter-over-quarter to $4.86B.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.